Related references
Note: Only part of the references are listed.Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
The Dual Role of Autophagy in Cancer Development and a Therapeutic Strategy for Cancer by Targeting Autophagy
Chul Won Yun et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial
Kjetil Boye et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2021)
Targeting autophagy enhances atezolizumab-induced mitochondria-related apoptosis in osteosarcoma
Zhuochao Liu et al.
CELL DEATH & DISEASE (2021)
Tumor microenvironment as a therapeutic target in cancer
Yi Xiao et al.
PHARMACOLOGY & THERAPEUTICS (2021)
Current research progress in targeted anti-angiogenesis therapy for osteosarcoma
Yun Liu et al.
CELL PROLIFERATION (2021)
The Heterogeneity of Infiltrating Macrophages in Metastatic Osteosarcoma and Its Correlation with Immunotherapy
Zhanchao Wang et al.
JOURNAL OF ONCOLOGY (2021)
Pathways of immune exclusion in metastatic osteosarcoma are associated with inferior patient outcomes
John A. Ligon et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Expression of programmed death ligand 1 in drug-resistant osteosarcoma: An exploratory study
Nicholas J. Skertich et al.
SURGERY OPEN SCIENCE (2021)
Small-molecule CSF1R kinase inhibitors; review of patents 2015-present
William A. Denny et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2021)
A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors
Jih-Hsiang Lee et al.
INVESTIGATIONAL NEW DRUGS (2020)
IMMUNITY, HYPOXIA, AND METABOLISM-THE MENAGE A TROIS OF CANCER: IMPLICATIONS FOR IMMUNOTHERAPY
Carla Riera-Domingo et al.
PHYSIOLOGICAL REVIEWS (2020)
Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update
Jinyun Dong et al.
DRUG RESISTANCE UPDATES (2020)
PD-1 and PD-L1 Expression in Osteosarcoma: Which Specimen to Evaluate?
Sonja Chen et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2020)
Mifamurtide and TAM-like macrophages: effect on proliferation, migration and differentiation of osteosarcoma cells
Francesca Punzo et al.
Oncotarget (2020)
Reprograming the tumor immunologic microenvironment using neoadjuvant chemotherapy in osteosarcoma
Chuangzhong Deng et al.
CANCER SCIENCE (2020)
The future of cancer immunotherapy: microenvironment-targeting combinations
Yonina R. Murciano-Goroff et al.
CELL RESEARCH (2020)
Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice
David Kung-Chun Chiu et al.
GASTROENTEROLOGY (2020)
Basic and Therapeutic Aspects of Angiogenesis Updated
Guy Eelen et al.
CIRCULATION RESEARCH (2020)
Immune Landscape of the Tumor Microenvironment Identifies Prognostic Gene Signature CD4/CD68/CSF1R in Osteosarcoma
Yi-jiang Song et al.
FRONTIERS IN ONCOLOGY (2020)
CXCL13/CXCR5 Interaction Facilitates VCAM-1-Dependent Migration in Human Osteosarcoma
Ju-Fang Liu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
Jeong A. Park et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Single-cell RNA landscape of intratumoral heterogeneity and immunosuppressive microenvironment in advanced osteosarcoma
Yan Zhou et al.
NATURE COMMUNICATIONS (2020)
Macrophages in Osteosarcoma Immune Microenvironment: Implications for Immunotherapy
Zhong-Wei Luo et al.
FRONTIERS IN ONCOLOGY (2020)
Metabolic reprogramming in tumors: Contributions of the tumor microenvironment
Andrew N. Lane et al.
GENES & DISEASES (2020)
Nanoparticle enhanced MRI can monitor macrophage response to CD47 mAb immunotherapy in osteosarcoma
Suchismita Mohanty et al.
CELL DEATH & DISEASE (2019)
HIF Inhibitors: Status of Current Clinical Development
Jaleh Fallah et al.
CURRENT ONCOLOGY REPORTS (2019)
Visfatin is involved in the cisplatin resistance of osteosarcoma cells via upregulation of Snail and Zeb1
Dexing Wang et al.
CANCER BIOLOGY & THERAPY (2019)
Interaction of tumor-associated macrophages and cancer chemotherapy
Irina Larionova et al.
ONCOIMMUNOLOGY (2019)
Inhibition of M2-like macrophages by all-trans retinoic acid prevents cancer initiation and stemness in osteosarcoma cells
Xue-jing Shao et al.
ACTA PHARMACOLOGICA SINICA (2019)
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
William D. Tap et al.
LANCET (2019)
ABC transporters in drug-resistant epilepsy: mechanisms of upregulation and therapeutic approaches
Kevin Leandro et al.
PHARMACOLOGICAL RESEARCH (2019)
Specific inhibition of PI3Kδ/γ enhances the efficacy of anti-PD1 against osteosarcoma cancer
Xinge Shi et al.
JOURNAL OF BONE ONCOLOGY (2019)
Role of autophagy in osteosarcoma
Olivier Camuzard et al.
JOURNAL OF BONE ONCOLOGY (2019)
Advances in immune checkpoint inhibitors for bone sarcoma therapy
Pichaya Thanindratarn et al.
JOURNAL OF BONE ONCOLOGY (2019)
Improving the efficacy of osteosarcoma therapy: combining drugs that turn cancer cell 'don't eat me' signals off and 'eat me' signals on
Suchismita Mohanty et al.
MOLECULAR ONCOLOGY (2019)
Targeting Autophagy in Cancer: Recent Advances and Future Directions
Ravi K. Amaravadi et al.
CANCER DISCOVERY (2019)
Anti-CD47 antibody eliminates bone tumors in rats
Shiqiang Fang et al.
SAUDI JOURNAL OF BIOLOGICAL SCIENCES (2019)
Overcoming cisplatin resistance in osteosarcoma through the miR-199a-modulated inhibition of HIF-1α
Ajimu Keremu et al.
BIOSCIENCE REPORTS (2019)
SDF-1/CXCR4 axis facilitates myeloid-derived suppressor cells accumulation in osteosarcoma microenvironment and blunts the response to anti-PD-1 therapy
Kuo Jiang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2019)
Role of hypoxia in cancer therapy by regulating the tumor microenvironment
Xinming Jing et al.
MOLECULAR CANCER (2019)
Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer
Hauke Stamm et al.
ONCOIMMUNOLOGY (2019)
Tumor-associated macrophages promote lung metastasis and induce epithelial-mesenchymal transition in osteosarcoma by activating the COX-2/STAT3 axis
Yu Han et al.
CANCER LETTERS (2019)
Metformin induces CD11b+-cell-mediated growth inhibition of an osteosarcoma: implications for metabolic reprogramming of myeloid cells and anti-tumor effects
Takenori Uehara et al.
INTERNATIONAL IMMUNOLOGY (2019)
Tisagenlecleucel - the first approved CAR-T-cell therapy: implications for payers and policy makers
Vinay Prasad
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Diego Chowell et al.
SCIENCE (2018)
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
V. Gopalakrishnan et al.
SCIENCE (2018)
CRISPRed Macrophages for Cell-Based Cancer Immunotherapy
Moumita Ray et al.
BIOCONJUGATE CHEMISTRY (2018)
Advances in Hypoxia-Inducible Factor Biology
Hani Choudhry et al.
CELL METABOLISM (2018)
Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints
Tao Shi et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
R. J. Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A short field guide to fibroblast function in immunity
Matthew B. Buechler et al.
SEMINARS IN IMMUNOLOGY (2018)
Anti-PD-1 therapy redirects macrophages from an M2 to an M1 phenotype inducing regression of OS lung metastases
Pooja Dhupkar et al.
CANCER MEDICINE (2018)
Bone sarcomas: ESMO-PaedCan-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. G. Casali et al.
ANNALS OF ONCOLOGY (2018)
Increased PD-L1 and T-cell infiltration in the presence of HLA class I expression in metastatic high-grade osteosarcoma: a rationale for T-cell-based immunotherapy
Yayan T. Sundara et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy
Fariba Navid et al.
INTERNATIONAL JOURNAL OF CANCER (2017)
Is CD47 an innate immune checkpoint for tumor evasion?
Xiaojuan Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial
Hussein A. Tawbi et al.
LANCET ONCOLOGY (2017)
Mxd1 mediates hypoxia-induced cisplatin resistance in osteosarcoma cells by repression of the PTEN tumor suppressor gene
Datong Zheng et al.
MOLECULAR CARCINOGENESIS (2017)
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
J. D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
PD-1 and PD-L1 expression in bone and soft tissue sarcomas
Alireza Torabi et al.
PATHOLOGY (2017)
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Moshe Sade-Feldman et al.
NATURE COMMUNICATIONS (2017)
Evaluation of HLA-G, HLA-E, and PD-L1 proteins in oral osteosarcomas
Diego Antonio Costa Arantes et al.
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY (2017)
Replication Study: The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors
Stephen K. Horrigan
ELIFE (2017)
Cancer Stem Cells and Their Microenvironment: Biology and Therapeutic Implications
Eunice Yuen-Ting Lau et al.
STEM CELLS INTERNATIONAL (2017)
Hypoxia promotes chemotherapy resistance by down-regulating SKA1 gene expression in human osteosarcoma
Qiong Ma et al.
CANCER BIOLOGY & THERAPY (2017)
Inhibition of IL-18-mediated myeloid derived suppressor cell accumulation enhances anti-PD1 efficacy against osteosarcoma cancer
Ying Guan et al.
JOURNAL OF BONE ONCOLOGY (2017)
Molecular genetics of osteosarcoma
Kirby Rickel et al.
BONE (2017)
Microenvironmental regulation of tumour angiogenesis
Michele de Palma et al.
NATURE REVIEWS CANCER (2017)
Progress in tumor-associated macrophage (TAM)-targeted therapeutics
Chayanon Ngambenjawong et al.
ADVANCED DRUG DELIVERY REVIEWS (2017)
Tumor microenvironment and therapeutic response
Ting Wu et al.
CANCER LETTERS (2017)
miR-335 negatively regulates osteosarcoma stem cell-like properties by targeting POU5F1
Xiaodong Guo et al.
CANCER CELL INTERNATIONAL (2017)
Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors
Melinda S. Merchant et al.
CLINICAL CANCER RESEARCH (2016)
TGF-β1-induced miR-202 mediates drug resistance by inhibiting apoptosis in human osteosarcoma
Zaijun Lin et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2016)
Combination cancer immunotherapies tailored to the tumour microenvironment
Mark J. Smyth et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
MicroRNA-30a downregulation contributes to chemoresistance of osteosarcoma cells through activating Beclin-1-mediated autophagy
Ruida Xu et al.
ONCOLOGY REPORTS (2016)
Coinhibitory Pathways in Immunotherapy for Cancer
Susanne H. Baumeister et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 34 (2016)
L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity
Roger Geiger et al.
CELL (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
Vinit Kumar et al.
TRENDS IN IMMUNOLOGY (2016)
Hypoxia-inducible microRNA-488 regulates apoptosis by targeting Bim in osteosarcoma
Chusong Zhou et al.
CELLULAR ONCOLOGY (2016)
Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas
Adrienne H. Long et al.
CANCER IMMUNOLOGY RESEARCH (2016)
Inhibition of Growth and Metastasis of Tumor in Nude Mice after Intraperitoneal Injection of Bevacizumab
Ze-xue Zhao et al.
ORTHOPAEDIC SURGERY (2016)
Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma
Pratistha Koirala et al.
SCIENTIFIC REPORTS (2016)
MiR-367 negatively regulates apoptosis induced by adriamycin in osteosarcoma cells by targeting KLF4
Guang-Chao Wang et al.
JOURNAL OF BONE ONCOLOGY (2016)
Hypoxia promotes drug resistance in osteosarcoma cells via activating AMP-activated protein kinase (AMPK) signaling
Changfu Zhao et al.
JOURNAL OF BONE ONCOLOGY (2016)
Notch1 is associated with the multidrug resistance of hypoxic osteosarcoma by regulating MRP1 gene expression
C. Li et al.
NEOPLASMA (2016)
Hypoxia-induced autophagy as an additional mechanism in human osteosarcoma radioresistance
Helin Feng et al.
JOURNAL OF BONE ONCOLOGY (2016)
Defective autophagy leads to the suppression of stem-like features of CD271+ osteosarcoma cells
Dong Zhang et al.
JOURNAL OF BIOMEDICAL SCIENCE (2016)
MicroRNA-301a modulates doxorubicin resistance in osteosarcoma cells by targeting AMP-activated protein kinase alpha 1
Yuanmin Zhang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
Mechanisms of Drug Resistance Related to the Microenvironment of Solid Tumors and Possible Strategies to Inhibit Them
Qian Tan et al.
CANCER JOURNAL (2015)
Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner
L. Fernandez et al.
CANCER LETTERS (2015)
Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
Chih-Hao Chang et al.
CELL (2015)
Bone microenvironment signals in osteosarcoma development
Arantzazu Alfranca et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2015)
Autophagy, Metabolism, and Cancer
Eileen White et al.
CLINICAL CANCER RESEARCH (2015)
Acridine Orange is an Effective Anti-Cancer Drug that Affects Mitochondrial Function in Osteosarcoma Cells
Caterina Fotia et al.
CURRENT PHARMACEUTICAL DESIGN (2015)
Challenges of cancer therapy with natural killer cells
Hans Klingemann
CYTOTHERAPY (2015)
Re: Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Timothy J. Daskivich et al.
EUROPEAN UROLOGY (2015)
Molecular Connections between Cancer Cell Metabolism and the Tumor Microenvironment
Calvin R. Justus et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2015)
Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade
Elizabeth Buchbinder et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
Nabil Ahmed et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Osteosarcoma: Current Treatment and a Collaborative Pathway to Success
Michael S. Isakoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The interaction of anticancer therapies with tumor-associated macrophages
Alberto Mantovani et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2015)
Enhanced T-Cell Immunity to Osteosarcoma Through Antibody Blockade of PD-1/PD-L1 Interactions
Danielle M. Lussier et al.
JOURNAL OF IMMUNOTHERAPY (2015)
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial
Giovanni Grignani et al.
LANCET ONCOLOGY (2015)
Paxilitaxel induces apoptosis accompanied by protective autophagy in osteosarcoma cells through hypoxia-inducible factor-1α pathway
Yuanqing Guo et al.
MOLECULAR MEDICINE REPORTS (2015)
T cell exclusion, immune privilege, and the tumor microenvironment
Johanna A. Joyce et al.
SCIENCE (2015)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12
Theofanis Floros et al.
SEMINARS IN ONCOLOGY (2015)
Macrophages and cancer: from mechanisms to therapeutic implications
Renato Ostuni et al.
TRENDS IN IMMUNOLOGY (2015)
CD47 blockade inhibits tumor progression human osteosarcoma in xenograft models
Ji-Feng Xu et al.
ONCOTARGET (2015)
Utilizing chimeric antigen receptors to direct natural killer cell activity
David L. Hermanson et al.
FRONTIERS IN IMMUNOLOGY (2015)
PD-L1 and CD8+PD1+ lymphocytes exist as targets in the pediatric tumor microenvironment for immunomodulatory therapy
Ferdousi Chowdhury et al.
ONCOIMMUNOLOGY (2015)
Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma
Danielle M. Lussier et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Improved Survival in Osteosarcoma Patients with Atypical Low Vascularization
Pierre Kunz et al.
ANNALS OF SURGICAL ONCOLOGY (2015)
Expression of programmed death 1 is correlated with progression of osteosarcoma
Wenjie Zheng et al.
APMIS (2015)
Pazopanib in metastatic osteosarcoma: Significant clinical response in three consecutive patients
Akmal Safwat et al.
ACTA ONCOLOGICA (2014)
Targeting the PD-1 pathway: a promising future for the treatment of melanoma
Andrew Mamalis et al.
ARCHIVES OF DERMATOLOGICAL RESEARCH (2014)
A novel ATG4B antagonist inhibits autophagy and has a negative impact on osteosarcoma tumors
Debra Akin et al.
AUTOPHAGY (2014)
Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells
Brian Ruffell et al.
CANCER CELL (2014)
HIF Transcription Factors, Inflammation, and Immunity
Asis Palazon et al.
IMMUNITY (2014)
Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ
Jens H. W. Pahl et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2014)
CTLA-4 Is Expressed by Activated Mouse NK Cells and Inhibits NK Cell IFN-γ Production in Response to Mature Dendritic Cells
Ana Stojanovic et al.
JOURNAL OF IMMUNOLOGY (2014)
Tumor stroma: a complexity dictated by the hypoxic tumor microenvironment
A. Casazza et al.
ONCOGENE (2014)
Macrophages mediate gemcitabine resistance of pancreatic adenocarcinoma by upregulating cytidine deaminase
N. Weizman et al.
ONCOGENE (2014)
Involvement of HIF-1α activation in the doxorubicin resistance of human osteosarcoma cells
Laura Roncuzzi et al.
ONCOLOGY REPORTS (2014)
Down Regulation of Wnt Signaling Mitigates Hypoxia-Induced Chemoresistance in Human Osteosarcoma Cells
Donald J. Scholten et al.
PLOS ONE (2014)
Programmed Cell Death Ligand 1 Expression in Osteosarcoma
Jacson K. Shen et al.
CANCER IMMUNOLOGY RESEARCH (2014)
Association between CTLA-4 genetic polymorphisms and susceptibility to osteosarcoma in Chinese Han population
Jinshan He et al.
ENDOCRINE (2014)
Effect of bevacizumab on angiogenesis and growth of canine osteosarcoma cells xenografted in athymic mice
Valery E. Scharf et al.
AMERICAN JOURNAL OF VETERINARY RESEARCH (2013)
The role of proton dynamics in the development and maintenance of multidrug resistance in cancer
Chloe Daniel et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2013)
Impeding Macrophage Entry into Hypoxic Tumor Areas by Sema3A/Nrp1 Signaling Blockade Inhibits Angiogenesis and Restores Antitumor Immunity
Andrea Casazza et al.
CANCER CELL (2013)
Chemotherapy Alters Monocyte Differentiation to Favor Generation of Cancer-Supporting M2 Macrophages in the Tumor Microenvironment
Eveline M. Dijkgraaf et al.
CANCER RESEARCH (2013)
Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors
Fariba Navid et al.
CLINICAL CANCER RESEARCH (2013)
Angiogenic factors in bone local environment
Shek Man Chim et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2013)
Macrophage plasticity and polarization in tissue repair and remodelling
Alberto Mantovani et al.
JOURNAL OF PATHOLOGY (2013)
Genome-wide association study identifies two susceptibility loci for osteosarcoma
Sharon A. Savage et al.
NATURE GENETICS (2013)
Enhancement of antitumor immunity by combining anti-cytotoxic T lymphocyte antigen-4 antibodies and cryotreated tumor lysate-pulsed dendritic cells in murine osteosarcoma
Masanori Kawano et al.
ONCOLOGY REPORTS (2013)
A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study
G. Grignani et al.
ANNALS OF ONCOLOGY (2012)
Imaging Tumor-Stroma Interactions during Chemotherapy Reveals Contributions of the Microenvironment to Resistance
Elizabeth S. Nakasone et al.
CANCER CELL (2012)
A CXCL1 Paracrine Network Links Cancer Chemoresistance and Metastasis
Swarnali Acharyya et al.
CELL (2012)
Results of a phase II study of sirolimus and cyclophosphamide in patients with advanced sarcoma
Scott M. Schuetze et al.
EUROPEAN JOURNAL OF CANCER (2012)
Indoleamine 2,3-dioxygenase, a new prognostic marker in sentinel lymph nodes of melanoma patients
Reinhart Speeckaert et al.
EUROPEAN JOURNAL OF CANCER (2012)
NK cells engineered to express a GD2-specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin
Ruth Esser et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2012)
Phase II Trial of Trastuzumab in Combination With Cytotoxic Chemotherapy for Treatment of Metastatic Osteosarcoma With Human Epidermal Growth Factor Receptor 2 Overexpression: A Report From the Children's Oncology Group
David Ebb et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Re: Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer Editorial Comment
Samir S. Taneja
JOURNAL OF UROLOGY (2012)
Initial testing of the multitargeted kinase inhibitor pazopanib by the pediatric preclinical testing program
Stephen T. Keir et al.
PEDIATRIC BLOOD & CANCER (2012)
PD-1 Expression on Natural Killer Cells and CD8+ T Cells During Chronic HIV-1 Infection
Sonia Norris et al.
VIRAL IMMUNOLOGY (2012)
Coordinated regulation of myeloid cells by tumours
Dmitry I. Gabrilovich et al.
NATURE REVIEWS IMMUNOLOGY (2012)
Addition of Pamidronate to Chemotherapy for the Treatment of Osteosarcoma
Paul A. Meyers et al.
CANCER (2011)
Macrophage Binding to Receptor VCAM-1 Transmits Survival Signals in Breast Cancer Cells that Invade the Lungs
Qing Chen et al.
CANCER CELL (2011)
Phase I and Pharmacokinetic Study of Sunitinib in Pediatric Patients with Refractory Solid Tumors: A Children's Oncology Group Study
Steven G. DuBois et al.
CLINICAL CANCER RESEARCH (2011)
Cytotoxic T-lymphocyte Antigen-4 Polymorphisms and Susceptibility to Osteosarcoma
Yang Liu et al.
DNA AND CELL BIOLOGY (2011)
Mifamurtide for the treatment of nonmetastatic osteosarcoma
Kosei Ando et al.
EXPERT OPINION ON PHARMACOTHERAPY (2011)
Macrophages and cathepsin proteases blunt chemotherapeutic response in breast cancer
Tanaya Shree et al.
GENES & DEVELOPMENT (2011)
MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy
James Finke et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2011)
Pediatric Phase I Trial and Pharmacokinetic Study of Dasatinib: A Report From the Children's Oncology Group Phase I Consortium
Richard Aplenc et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Drug Resistance and Cellular Adaptation to Tumor Acidic pH Microenvironment
Jonathan W. Wojtkowiak et al.
MOLECULAR PHARMACEUTICS (2011)
NORMALIZATION OF THE VASCULATURE FOR TREATMENT OF CANCER AND OTHER DISEASES
Shom Goel et al.
PHYSIOLOGICAL REVIEWS (2011)
Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells
Masahisa Jinushi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy
David G. DeNardo et al.
CANCER DISCOVERY (2011)
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody
Don M. Benson et al.
BLOOD (2010)
Macrophage Diversity Enhances Tumor Progression and Metastasis
Bin-Zhi Qian et al.
CELL (2010)
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
Mojgan Ahmadzadeh et al.
BLOOD (2009)
Addition of Muramyl Tripeptide to Chemotherapy for Patients With Newly Diagnosed Metastatic Osteosarcoma
Alexander J. Chou et al.
CANCER (2009)
Osteosarcoma Incidence and Survival Rates From 1973 to 2004 Data From the Surveillance, Epidemiology, and End Results Program
Lisa Mirabello et al.
CANCER (2009)
Arginase I-Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes
Paulo C. Rodriguez et al.
CANCER RESEARCH (2009)
Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma
Hiroshi Urakawa et al.
CLINICAL & EXPERIMENTAL METASTASIS (2009)
International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons
Lisa Mirabello et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Interferon-γ reverses the immunosuppressive and protumoral properties and prevents the generation of human tumor-associated macrophages
Dorothee Duluc et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways
Ymera Pignochino et al.
MOLECULAR CANCER (2009)
Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal
Brian T. Fife et al.
NATURE IMMUNOLOGY (2009)
Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival - A report from the Children's Oncology Group
Paul A. Meyers et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program
John M. Maris et al.
PEDIATRIC BLOOD & CANCER (2008)
Macrophage polarization in tumour progression
Antonio Sica et al.
SEMINARS IN CANCER BIOLOGY (2008)
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: A children's oncology group study
Mason Bond et al.
PEDIATRIC BLOOD & CANCER (2008)
Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells
Farbod Shojaei et al.
NATURE BIOTECHNOLOGY (2007)
Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer
Srinivas Nagaraj et al.
NATURE MEDICINE (2007)
Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back
Monica M. Bertagnolli
LANCET ONCOLOGY (2007)
Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer:: Effect on tumor-infiltrating T cells
G Brandacher et al.
CLINICAL CANCER RESEARCH (2006)
Osteosarcoma: A randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate
PA Meyers et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Radiotherapy for local control of osteosarcoma
TF DeLaney et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
Postrelapse survival in osteosarcoma of the extremities: Prognostic factors for long-term survival
S Ferrari et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction
C Uherek et al.
BLOOD (2002)
CTLA-4: new insights into its biological function and use in tumor immunotherapy
JG Egen et al.
NATURE IMMUNOLOGY (2002)
Share Paper
